Literature DB >> 11071064

Apolipoprotein E polymorphism and serum concentration in Alzheimer's disease in nine European centres: the ApoEurope study. ApoEurope group.

G Siest1, P Bertrand, B Qin, B Herbeth, J M Serot, L Masana, J Ribalta, A P Passmore, A Evans, M Ferrari, M Franceschi, J Shepherd, M Cuchel, U Beisiegel, K Zuchowsky, A S Rukavina, J Sertic, M Stojanov, V Kostic, A Mitrevski, V Petrova, C Sass, A Merched, J T Salonen, L Tiret, S Visvikis.   

Abstract

As part of the ApoEurope Project, apolipoprotein E (apo E) common polymorphism and serum concentration were determined in 489 Alzheimer's disease patients and 429 controls. Patients and controls were recruited through nine centres in eight European countries. Age, sex ratios and education levels of both case and control populations were similar, although discrete differences appeared between centres. The prevalence of the epsilon4 allele was higher in Alzheimer's disease than in controls (increased by 140%), while serum apo E concentration was lower by 11.2% (p<0.001). In addition, serum total cholesterol and triglyceride concentrations were lower in Alzheimer's disease (p<0.001), while that of apo Al was not affected. The decrease in serum apo E concentration was not accounted for by the epsilon4 allele, age or gender, suggesting that apo E concentration might represent an additional risk factor for Alzheimer's disease, complementary and independent of the epsilon4 allele. Further analysis will be aimed at determining whether the quantitative link between apo E concentration and Alzheimer's disease occurs through the effect of apo E genotype on lipid parameters or by other mechanisms.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11071064     DOI: 10.1515/CCLM.2000.102

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  27 in total

1.  Preferential interactions between ApoE-containing lipoproteins and Aβ revealed by a detection method that combines size exclusion chromatography with non-reducing gel-shift.

Authors:  Mary Jo LaDu; Gregory W Munson; Lisa Jungbauer; Godfrey S Getz; Catherine A Reardon; Leon M Tai; Chunjiang Yu
Journal:  Biochim Biophys Acta       Date:  2011-11-23

2.  Plasma signaling proteins in persons at genetic risk for Alzheimer disease: influence of APOE genotype.

Authors:  John M Ringman; David Elashoff; Daniel H Geschwind; Brian T Welsh; Karen H Gylys; Cathy Lee; Jeffrey L Cummings; Greg M Cole
Journal:  Arch Neurol       Date:  2012-06

Review 3.  Biomarkers of Alzheimer disease in plasma.

Authors:  Michael C Irizarry
Journal:  NeuroRx       Date:  2004-04

4.  Relationship between low levels of high-density lipoprotein cholesterol and dementia in the elderly. The InChianti study.

Authors:  G Zuliani; M Cavalieri; M Galvani; S Volpato; A Cherubini; S Bandinelli; A M Corsi; F Lauretani; J M Guralnik; R Fellin; L Ferrucci
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2010-03-18       Impact factor: 6.053

5.  Low plasma ApoE levels are associated with smaller hippocampal size in the Alzheimer's disease neuroimaging initiative cohort.

Authors:  Edmond Teng; Nicole Chow; Kristy S Hwang; Paul M Thompson; Karen H Gylys; Gregory M Cole; Clifford R Jack; Leslie M Shaw; John Q Trojanowski; Holly D Soares; Michael W Weiner; Liana G Apostolova
Journal:  Dement Geriatr Cogn Disord       Date:  2014-12-24       Impact factor: 2.959

Review 6.  'Evolutionary medicine' perspectives on Alzheimer's Disease: Review and new directions.

Authors:  Molly Fox
Journal:  Ageing Res Rev       Date:  2018-07-27       Impact factor: 10.895

7.  An apolipoprotein E4 fragment affects matrix metalloproteinase 9, tissue inhibitor of metalloproteinase 1 and cytokine levels in brain cell lines.

Authors:  I Dafnis; A K Tzinia; E C Tsilibary; V I Zannis; A Chroni
Journal:  Neuroscience       Date:  2012-03-14       Impact factor: 3.590

Review 8.  Blood-based biomarkers of Alzheimer's disease: challenging but feasible.

Authors:  Madhav Thambisetty; Simon Lovestone
Journal:  Biomark Med       Date:  2010-02       Impact factor: 2.851

9.  CYP46 T/C polymorphism is not associated with Alzheimer's dementia in a population from Hungary.

Authors:  Anna Juhász; Agnes Rimanóczy; Krisztina Boda; Gábor Vincze; Gyozo Szlávik; Marianna Zana; Annamária Bjelik; Magdolna Pákáski; Nikoletta Bódi; András Palotás; Zoltán Janka; János Kálmán
Journal:  Neurochem Res       Date:  2005-08       Impact factor: 3.996

10.  Plasma proteomics for the identification of Alzheimer disease.

Authors:  Liang-Hao Guo; Panagiotis Alexopoulos; Stefan Wagenpfeil; Alexander Kurz; Robert Perneczky
Journal:  Alzheimer Dis Assoc Disord       Date:  2013 Oct-Dec       Impact factor: 2.703

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.